Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia.
Diego Antonio Pereira-MartinsJuan L Coelho-SilvaIsabel WeinhäuserPedro L Franca-NetoDouglas Rafaele Almeida SilveiraCésar OrtizAmanda Moreira-AguiarMarinus M LimaLuisa C KouryRaul A de MeloAna B GlóriaEvandro M FagundesBruno Kosa L DuarteKatia B B PagnanoRosane BittencourtElenaide NunesFabiola TrainaLorena Figueiredo-PontesArmand KeatingMartin S TallmanRaul C RibeiroRichard DilonArnold GanserMiguel A SanzNancy BerlinerPeter ValkBob LöwenbergTiziana OttoneNelida Inés NogueraMaria Teresa Teresa VosoFrancesca PaoloniPaola FaziEmanuele AmmatunaGerwin HulsJan Jacob SchuringaEduardo Magalhaes RegoAntônio Roberto Lucena de AraujoPublished in: British journal of haematology (2022)
Although a growing body of evidence demonstrates that altered mtDNA content (mtDNAc) has clinical implications in several types of solid tumours, its prognostic relevance in acute promyelocytic leukaemia (APL) patients remains largely unknown. Here, we show that patients with higher-than-normal mtDNAc had better outcomes regardless of tumour burden. These results were more evident in patients with low-risk of relapse. The multivariate Cox proportional hazard model demonstrated that high mtDNAc was independently associated with a decreased cumulative incidence of relapse. Altogether, our data highlights the possible role of mitochondrial metabolism in APL patients treated with ATRA.
Keyphrases
- mitochondrial dna
- copy number
- liver failure
- end stage renal disease
- respiratory failure
- ejection fraction
- chronic kidney disease
- newly diagnosed
- drug induced
- risk factors
- peritoneal dialysis
- prognostic factors
- free survival
- data analysis
- hepatitis b virus
- intensive care unit
- big data
- gene expression
- genome wide
- skeletal muscle
- deep learning
- mechanical ventilation
- glycemic control